TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02802098
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
Study: NCT02271425
Drug: Evacetrapib Tablet
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02271425
Drug: Evacetrapib Intravenous
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT01001832
Drug: Intravenous (IV) abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
Study: NCT01001832
Drug: Subcutaneous (SC) abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
Study: NCT02425930
Drug: S-1+Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
Study: NCT00256451
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/day for two days prior to the alcohol challenge session
Study: NCT00216372
Drug: Lanreotide (microparticle formulation)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
Study: NCT00568945
Drug: Capadenoson (BAY68-4986)
Normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg BAY68-4986 for five days
Study: NCT02425683
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
Study: NCT00747214
Drug: CRx-102
Normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00508976
Drug: Injected bupivacaine post-operatively
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study: NCT00508976
Drug: Streamed bupivacaine versus streamed normal saline
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study: NCT00508976
Drug: Aerosolized bupivacaine versus aerosolized saline
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study: NCT00508976
Drug: Injected lidocaine pre-incision vs saline pre-incision
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study: NCT03423264
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin taken as follows:~Day 1 (evening): 600 mg Day 2 (morning): 600 mg Day 2 (evening): 600 mg Day 3 (morning): 600 mg Day 3 (evening): 900 mg Day 4 (morning): 900 mg Day 4 (evening): 900 mg Day 5 (morning): 900 mg Day 5 (noon): 900 mg Day 5 (evening): 900 mg
Study: NCT01013285
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02861261
Drug: 1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study: NCT00465179
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg by mouth daily for 4 weeks, then 2 weeks off.
Study: NCT01933594
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RMD administered over 4 hours via an intravenous (IV) catheter.
Study: NCT01933594
Drug: Placebo for Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo for RMD administered over 4 hours via an IV catheter.
Study: NCT03012646
Drug: Inhaled Treprostinil
Normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled treprostinil (6 mcg/breath) administered four times daily
Study: NCT02861261
Drug: 1. Berberine placebo tablets ; 2. ProMetS probiotics powder
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study: NCT01498289
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
Study: NCT01498289
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
Study: NCT01498289
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
Study: NCT02805608
Drug: Injection of 68Ga-NOTA-AE105
Normalized name: sodium bicarbonate Injection [Neut brand of sodium bicarbonate]
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One injection intravenously of 68Ga-NOTA-AE105
Study: NCT02805608
Drug: Injection of 18F-FDG
Normalized name: (18F)-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One injection intravenously of 18F-FDG
Study: NCT02954068
Drug: IV Oxytocin + IM placebo
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02954068
Drug: IM Oxytocin + IV placebo
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00833755
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
Study: NCT02182557
Drug: Ketotifen Fumarate Dry Syrup
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02182557
Drug: Ketotifen Fumarate Dry Syrup placebo
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03797079
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
Study: NCT01292408
Drug: Hydrochloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg per os once, and then 400 mg per day
Study: NCT00244439
Drug: Permethrin 1%
Normalized name: PERMETHRIN 1% LIQUID,TOP
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 minute application
Study: NCT00471497
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
Study: NCT00471497
Drug: imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
Study: NCT04163874
Drug: Fiasp
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fiasp Insulin delivered in a basal-bolus manner.
Study: NCT04163874
Drug: Pramlintide Acetate
Normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
Study: NCT00981617
Drug: ALKS33 (RDC-0313) (1 mg)
Normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Study: NCT00981617
Drug: ALKS33 (RDC-0313) (2.5 mg)
Normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Study: NCT00981617
Drug: ALKS33 (RDC-0313) (10 mg)
Normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Study: NCT00605020
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00605020
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01990118
Drug: Neoral
Normalized name: Neoral
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral® capsule containing 25mg or 100mg cyclosporine
Study: NCT01990118
Drug: Gengraf® capsule containing 25mg or 100mg cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant patients who were stable on Neoral were converted to Gengraf
Study: NCT04578782
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
Study: NCT01387269
Drug: Anamorelin HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anamorelin HCl will be orally administered daily at least one hour before meal
Study: NCT00236717
Drug: Topiramate; Carbamazepine; Valproate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02939547
Drug: Hydroxypropyl-beta-cyclodextrin
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
Study: NCT02041520
Drug: omega 3 fatty acids
Normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
Study: NCT00096811
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
Study: NCT00862628
Drug: Rebamipide
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 100mg tid, 4 or 8 weeks
Study: NCT02373410
Drug: Umbilicus Bupivacaine
Normalized name: Umbilicus rupestris extract
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Study: NCT02373410
Drug: Lowest rib margin Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Study: NCT02373410
Drug: Xiphoid Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Study: NCT02373410
Drug: Nipple Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Study: NCT02861261
Drug: 1. Berberine hydrochloride tablets; 2. Probiotics placebo powder
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night
Study: NCT01512888
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV).
Study: NCT01222299
Drug: bepotastine besilate nasal product - low dose
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sterile nasal product
Study: NCT01222299
Drug: bepotastine besilate nasal product - medium dose
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sterile nasal product
Study: NCT01222299
Drug: bepotastine besilate nasal product - high dose
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sterile nasal product
Study: NCT02861261
Drug: 1. Berberine placebo tablets; 2. Probiotics placebo powder
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night
Study: NCT03794778
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175 mg/m2, i.v.,d1; once every 21days
Study: NCT03794778
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 5, i.v.,d1; once every 21days,
Study: NCT04471987
Drug: IL12-L19L19
Normalized name: Immunocytokine NHS-IL12
DrugBank: Immunocytokine NHS-IL12 (DB17585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications.
Study: NCT04471987
Drug: IL12-L19L19
Normalized name: Immunocytokine NHS-IL12
DrugBank: Immunocytokine NHS-IL12 (DB17585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
Study: NCT01868477
Drug: Deferasirox DFX, DT
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: provided as dispersible tablets for oral use in 125 and 250, 500 mg
Study: NCT01868477
Drug: Erythropoietin alpha
Normalized name: alpha tocopherol
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01868477
Drug: Deferasirox DFX, FCT
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
Study: NCT00562965
Drug: inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
Study: NCT00562965
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
Study: NCT00562965
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous rituximab at a dose of 375 mg/m2 on day 1
Study: NCT00562965
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
Study: NCT00562965
Drug: prednisone/prednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
Study: NCT00562965
Drug: mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mitoxantrone 10 mg/m2 intravenous on day 2
Study: NCT00562965
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 25 mg/m2 intravenous on days 2 through 4
Study: NCT00562965
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral dexamethasone 20 mg/day on days 1-5
Study: NCT01972711
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-36385625 as a single oral dose of 50 mg
Study: NCT00847093
Drug: LMX4
Normalized name: LIDOCAINE 40 mg in 1 g TOPICAL CREAM [LMX4]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One inch every six hours
Study: NCT01972711
Drug: Amisulpride
Normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amisulpride as a single oral dose of 400 mg
Study: NCT00031551
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02554175
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol was administered to achieve target propofol Ce
Study: NCT02530541
Drug: CHG
Normalized name: CHGN111
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varied application times
Study: NCT04224116
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
Study: NCT01354925
Drug: Insulin treatment during Ramadan
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
Study: NCT04224116
Drug: SSI
Normalized name: Tussin
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Salin isotonic injected
Study: NCT00004233
Drug: triacetyluridine
Normalized name: Triacetyluridine
DrugBank: Uridine triacetate (DB09144)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01422226
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
Study: NCT03487874
Drug: 0.75% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots